Основная статистика
| CIK | 1815442 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kymera Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| September 3, 2025 |
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary EX-99.1 Exhibit 99.1 Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary Watertown, Mass. (September 3, 2025) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer |
|
| August 11, 2025 |
Amended and Restated Non-Employee Director Compensation Policy dated June 25, 2025. KYMERA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Kymera Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or i |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| August 11, 2025 |
Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses se |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2025 |
Letter between the Registrant and Genzyme Corporation, dated as of April 10, 2025. Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| June 27, 2025 |
Kymera Therapeutics Announces Proposed Public Offering Exhibit 99.1 Kymera Therapeutics Announces Proposed Public Offering Watertown, Mass. (June 25, 2025) – – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock |
|
| June 27, 2025 |
Kymera Therapeutics Announces Pricing of $250 Million Public Offering Exhibit 99.2 Kymera Therapeutics Announces Pricing of $250 Million Public Offering Watertown, Mass. (June 26, 2025) – – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its comm |
|
| June 27, 2025 |
EX-4.1 Exhibit 4.1 KYMERA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2025 Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 (June 25, 2025) KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporat |
|
| June 27, 2025 |
5,044,500 Shares of Common Stock Pre-Funded Warrants to Purchase 655,500 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-282912 PROSPECTUS SUPPLEMENT (To Prospectus dated October 31, 2024) 5,044,500 Shares of Common Stock Pre-Funded Warrants to Purchase 655,500 Shares of Common Stock We are offering 5,044,500 of shares of common stock and, in lieu of common stock, pre-funded warrants to purchase 655,500 shares of our common stock, to certain inv |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 27, 2025 |
EX-10.1 Exhibit 10.1 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of June 26, 2025 by and between Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (each, an “Investor”, and collectively, the “Investors”). Unless otherwise defined herein, capita |
|
| June 27, 2025 |
Exhibit 1.1 5,044,500 SHARES 655,500 PRE-FUNDED WARRANTS TO PURCHASE SHARES KYMERA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT June 26, 2025 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC Jefferies LLC TD Securities (USA) LLC Leerink Partners LLC c/o Morgan Stanley & Co. |
|
| June 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Kymera Therapeutics, Inc. |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 25, 2025 |
Exhibit 99.1 CONTACTS: Gilead Info Jessica Smith, Media [email protected] Jacquie Ross, Investors [email protected] Kymera Therapeutics Info Justine Koenigsberg Vice President, Investor Relations [email protected] [email protected] 857-285-5300 GILEAD SCIENCES AND KYMERA THERAPEUTICS ENTER INTO EXCLUSIVE OPTION AND LICENSE AGREEMENT TO DEVELOP NOVEL ORAL MOLECULAR GLUE CDK2 |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 25, 2025 |
$250,000,000 Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-282912 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to se |
|
| June 25, 2025 |
EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration mi |
|
| June 2, 2025 |
Exhibit 99.1 Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera’s target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 2, 2025 |
EX-99.1 Exhibit 99.1 June 2, 2025 KT-621 / STAT6 Degrader Phase 1 Healthy Volunteer Results Revolutionizing Immunology with Oral Small Molecule Degrader Medicines Agenda Introduction Justine Koenigsberg Vice President, Investor Relations Revolutionizing Immunology with Oral Medicines Nello Mainolfi, PhD Founder, President and Chief Executive Officer KT-621 Phase 1 Healthy Volunteer Data Jared Goll |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2025 |
Exhibit 99.2 Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically |
|
| May 9, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction (Commission (I.R.S. Employer of |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| May 9, 2025 |
Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, w |
|
| May 9, 2025 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| April 30, 2025 |
CORRESP VIA EDGAR April 30, 2025 Office of Life Sciences Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 29, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kymera Therapeutics, Inc. |
|
| February 27, 2025 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts ACTIVE/107610297.1 |
|
| February 27, 2025 |
Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEU |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| February 27, 2025 |
Amended and Restated Insider Trading Policy Exhibit 19.1 AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Kymera Therapeutics, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Policy”) is designed to prevent insider trading or the appearance of |
|
| February 10, 2025 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Kymera Therapeutics, Inc. |
|
| January 14, 2025 |
Nello Mainolfi, Ph.D., Founder, President and CEO J.P. Morgan Healthcare Conference January 2025 Exhibit 99.2 Nello Mainolfi, Ph.D., Founder, President and CEO J.P. Morgan Healthcare Conference January 2025 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, implied and express statements about strategy, business p |
|
| January 14, 2025 |
Exhibit 99.1 Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
KYMR / Kymera Therapeutics, Inc. / Atlas Venture Fund X, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428252d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kymera Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 501575104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Chec |
|
| November 14, 2024 |
SC 13G/A 1 p24-3101sc13ga.htm KYMERA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Stateme |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Kymera Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1 |
|
| November 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501575104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| October 31, 2024 |
As filed with the Securities and Exchange Commission on October 31, 2024 Table of Contents As filed with the Securities and Exchange Commission on October 31, 2024 Registration No. |
|
| October 31, 2024 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.4 KYMERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certific |
|
| October 31, 2024 |
EX-10.2 3 kymr-ex102.htm EX-10.2 Exhibit 10.2 OPEN MARKET SALE AGREEMENT1 October 31, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agen |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| October 31, 2024 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.5 KYMERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 202[•] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Ce |
|
| October 31, 2024 |
Letter between the Registrant and Genzyme Corporation, dated as of July 31, 2024. EX-10.1 2 kymr-ex101.htm EX-10.1 Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Kymera Therapeutics, Inc. 500 North Beacon Street, 4th Floor, Watertown, |
|
| October 31, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Kymera Therapeutics, Inc. |
|
| October 31, 2024 |
Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; c |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| August 22, 2024 |
KYMR / Kymera Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Kymera Therapeutics, Inc. |
|
| August 20, 2024 |
Kymera Therapeutics Announces Pricing of $225 Million Public Offering Exhibit 99.2 Kymera Therapeutics Announces Pricing of $225 Million Public Offering Watertown, Mass. (August 19, 2024) – – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $225 million of shares of its comm |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| August 20, 2024 |
2,002,313 Shares of Common Stock Pre-Funded Warrants to Purchase 3,519,159 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-259955 PROSPECTUS SUPPLEMENT (To Prospectus dated October 1, 2021) 2,002,313 Shares of Common Stock Pre-Funded Warrants to Purchase 3,519,159 Shares of Common Stock We are offering 2,002,313 shares of common stock and, in lieu of common stock, pre-funded warrants to purchase 3,519,159 shares of our common stock, to certain investors. Our common |
|
| August 20, 2024 |
Exhibit 1.1 2,002,313 SHARES 3,519,159 PRE-FUNDED WARRANTS TO PURCHASE SHARES KYMERA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT August 19, 2024 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC TD Securities (USA) LLC Stifel, Nicolaus & Company, Incorporated c/o Morgan Sta |
|
| August 20, 2024 |
Kymera Therapeutics Announces Proposed Public Offering Exhibit 99.1 Kymera Therapeutics Announces Proposed Public Offering Watertown, Mass. (August 19, 2024) – – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stoc |
|
| August 20, 2024 |
Exhibit 4.1 KYMERA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assig |
|
| August 19, 2024 |
$200,000,000 Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259955 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to se |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2024 |
Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 20 |
|
| July 8, 2024 |
Exhibit 99.1 Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy Watertown, Mass. (July 8, 2024) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminar |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 (June 18, 2024) KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporat |
|
| June 20, 2024 |
Amendment No. 1 to the 2020 Stock Option and Incentive Plan Exhibit 10.1 Amendment No. 1 to the 2020 Stock Option and Incentive Plan In accordance with Section 16 of Kymera Therapeutics, Inc. (the “Corporation”) 2020 Stock Option and Incentive Plan (the “Plan”), the Plan is hereby amended as follows, subject to approval of the Corporation’s stockholders: 1. Section 1 of the Plan is hereby amended to include the following as a new definition: “Outstanding S |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission F |
|
| May 2, 2024 |
Amended and Restated Non-Employee Director Compensation Policy dated March 27, 2024. Exhibit 10.1 KYMERA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Kymera Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| May 2, 2024 |
Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-2 |
|
| April 24, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 1, 2024 |
KYMR / Kymera Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2024 |
Agreement Regarding the Joint Filing of Schedule 13D by and among the Reporting Persons. EX-99.1 2 tm2410174d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Kymera Therapeutics, Inc. |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| February 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kymera Therapeutics, Inc. |
|
| February 22, 2024 |
Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in first half of 2025, both with Phase 1 data in 2025 Additio |
|
| February 22, 2024 |
As filed with the Securities and Exchange Commission on February 22, 2024 S-8 As filed with the Securities and Exchange Commission on February 22, 2024 Registration No. |
|
| February 22, 2024 |
Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. Exhibit 10.13 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made as of this 20th day of December, 2021, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and Kymera therapeutics, Inc., a Delaware corporation (“Tenant”). Building: The to-be-constructed building in the Project to be located at The Arsenal on the Charles, Watertown, Massachusetts 02472 (al |
|
| February 22, 2024 |
Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. Exhibit 10.3 KYMERA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Kymera Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| February 22, 2024 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts ACTIVE/107610297.1 |
|
| February 22, 2024 |
Exhibit 97 KYMERA COMPENSATION RECOVERY POLICY Adopted as of September 28, 2023 Kymera Therapeutics, Inc. |
|
| February 22, 2024 |
Letter between the Registrant and Genzyme Corporation, dated as of November 14, 2023. Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472 Attn: Chief Executive O |
|
| February 22, 2024 |
Certain identified information, MARKED BY “[***]”, has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| February 22, 2024 |
Exhibit 10.10 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND KYMERA THERAPEU |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEU |
|
| February 14, 2024 |
SC 13G/A 1 p24-0274sc13ga.htm KYMERA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statemen |
|
| February 13, 2024 |
KYMR / Kymera Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01304-kymeratherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Kymera Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 501575104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| February 9, 2024 |
KYMR / Kymera Therapeutics, Inc. / Atlas Venture Fund X, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm245794d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kymera Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check |
|
| February 8, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501575104 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 10, 2024 |
KYMR / Kymera Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242265d1sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 501575104 (CUSIP Number) JAMES KRAT |
|
| January 5, 2024 |
2,250,495 Shares of Common Stock Pre-Funded Warrants to Purchase 8,640,594 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259955 PRELIMINARY PROSPECTUS SUPPLEMENT (To Prospectus dated October 1, 2021) 2,250,495 Shares of Common Stock Pre-Funded Warrants to Purchase 8,640,594 Shares of Common Stock We are offering 2,250,495 of shares of common stock and, in lieu of common stock, pre-funded warrants to purchase 8,640,594 shares of our common |
|
| January 5, 2024 |
Kymera Therapeutics Announces Proposed Public Offering EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Proposed Public Offering Watertown, Mass. (January 4, 2024) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering of $250.0 million of shares of its commo |
|
| January 5, 2024 |
Kymera Therapeutics Announces Pricing of $275 Million Public Offering EX-99.2 Exhibit 99.2 Kymera Therapeutics Announces Pricing of $275 Million Public Offering Watertown, Mass. (January 5, 2024) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of $275 million of shares of it |
|
| January 5, 2024 |
EX-4.1 Exhibit 4.1 KYMERA THERAPEUTICS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2024 Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered ass |
|
| January 5, 2024 |
EX-1.1 Exhibit 1.1 2,250,495 SHARES 8,640,594 PRE-FUNDED WARRANTS TO PURCHASE SHARES KYMERA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT January 4, 2024 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New Yo |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| January 5, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Kymera Therapeutics, Inc. |
|
| January 4, 2024 |
Welcome Justine Koenigsberg Vice President, Investor Relations 2 Exhibit 99.1 2024 IMMUNOLOGY R&D DAY January 4, 2024 ©2023 KYMERA THERAPEUTICS, INC. PAGE 1 Welcome Justine Koenigsberg Vice President, Investor Relations 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements include, but are not limited to, im |
|
| January 4, 2024 |
$250,000,000 Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259955 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| January 4, 2024 |
EX-99.1 Exhibit 99.1 R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like a |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| November 2, 2023 |
EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update First patient dosed in KT-474/SAR444656 (IRAK4) Phase 2 HS clinical trial, generating a $40 million milestone payment from partner Sanofi; dosing of first patient in Phase 2 AD trial expected in the fourth quarter of 2023 ASH abstract to be released today highlights KT-333 (STAT3) |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| November 2, 2023 |
Exhibit 99.1 Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting Abstract released today highlights safety, pharmacodynamic and clinical response data collected through July 10, 2023 cut-off Updated data to be presented at the American Society of Hematology (ASH) 65th Annual Meeting and Exposition on December 10, 2023 Watertown |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| August 3, 2023 |
Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 trials for both hidradenitis suppurativa (HS) and atopic dermatitis (AD) planned to start in 4Q23 by partner Sanofi Phase 1 oncology trials for KT-253 (MDM2), KT-333 (STAT3), and KT-413 (IRAKIMiD) degraders ongoing, with clinical updates planned for later |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KYMERA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) Jonathan Biller Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 |
|
| May 22, 2023 |
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer EX-99.1 Exhibit 99.1 Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer Watertown, Mass. (May 22, 2023) – – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission F |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| May 4, 2023 |
Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2023 Financial Results and Provides a Business Update Phase 1 clinical trial of MDM2 degrader (KT-253) initiated KT-474 (SAR444656) Phase 2 planned to start in 2023; Kymera to present Phase 1 clinical data at EADV Symposium in May Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing, with program updates at ICML in June |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMIS SIO N Washington, D. |
|
| April 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| February 23, 2023 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts ACTIVE/107610297.1 |
|
| February 23, 2023 |
Exhibit 10.10 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT BETWEEN GENZYME CORPORATION AND KYMERA THERAPEU |
|
| February 23, 2023 |
Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update Partner Sanofi plans to initiate Phase 2 trial of IRAK4 degrader KT-474 (SAR444656) in 2023 Phase 1 trials for STAT3 (KT-333) and IRAKIMiD (KT-413) degraders ongoing, with data evaluating clinical activity expected to be shared in 2023 Phase 1 clinical trial for MDM2 degrad |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K fig` UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THE |
|
| February 23, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kymera Therapeutics, Inc. |
|
| February 23, 2023 |
Power of Attorney (included on signature page). S-8 As filed with the Securities and Exchange Commission on February 23, 2023 Registration No. |
|
| February 23, 2023 |
Certain identified information, MARKED BY “[***]”, has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| February 23, 2023 |
Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. Exhibit 10.3 KYMERA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Kymera Therapeutics, Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the |
|
| February 23, 2023 |
Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. Exhibit 10.13 LEASE AGREEMENT THIS LEASE AGREEMENT (this “Lease”) is made as of this 20th day of December, 2021, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and Kymera therapeutics, Inc., a Delaware corporation (“Tenant”). Building: The to-be-constructed building in the Project to be located at The Arsenal on the Charles, Watertown, Massachusetts 02472 (al |
|
| February 14, 2023 |
EX-99.1 2 tm236041d15ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 |
|
| February 14, 2023 |
EX-1 2 ex-1.htm JOINT FILING AGREEMENT Atlas Venture Fund X, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Kymera Therapeutics, Inc. and further |
|
| February 14, 2023 |
SC 13G/A 1 kymr-sc13ga021323.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kymera Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This |
|
| February 14, 2023 |
SC 13G 1 p23-0575sc13g.htm KYMERA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) C |
|
| February 14, 2023 |
KYMR / Kymera Therapeutics Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Kymera Therapeutics, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 14, 2023 |
KYMR / Kymera Therapeutics Inc / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm234999d17sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2023 |
EX-99.1 2 tm234999d17ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Kymera Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. February 14, 2023 BAKER BROS. AD |
|
| February 9, 2023 |
KYMR / Kymera Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01264-kymeratherapeuticsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Kymera Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 501575104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box t |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501575104 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| January 10, 2023 |
Exhibit 99.1 Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company WATERTOWN, Mass., January 10, 2023 – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| December 14, 2022 |
EX-99.1 Exhibit 99.1 Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorabl |
|
| December 14, 2022 |
EX-99.1 Exhibit 99.1 KT-474 HS and AD Clinical Data and Oncology Pipeline Update C o m p a n y W e b c a s t December 14, 2022 Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospect |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| November 3, 2022 |
EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update Completed patient cohort portion (Part C) of the IRAK4 degrader KT-474 Phase 1 trial Patient data from KT-474 and clinical oncology pipeline to be presented in December, 2022 Raised $150 million through private placement equity financing; September 30, 2022, cash balance of $596 m |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| November 3, 2022 |
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors EX-99.2 Exhibit 99.2 Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors Watertown, Mass. (November 3, 2022) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Victor Sandor, M.D.C. |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| October 13, 2022 |
Exhibit 99.1 Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1 dose escalation KT-253 has completed IND enabling studies Watertown, Mass. (October 13, 2022) ? Kymera Therapeutics, Inc. (NASDAQ: KYMR), a |
|
| September 6, 2022 |
5,769,228 Shares Common Stock Offered by the Selling Stockholders Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-259955 PROSPECTUS SUPPLEMENT (To Prospectus dated October 1, 2021) 5,769,228 Shares Common Stock Offered by the Selling Stockholders This prospectus supplement relates to the proposed resale or other disposition from time to time of up to (i) 2,769,228 shares of our common stock and (ii) 3,000,000 shares of our common stock is |
|
| September 6, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(3) (Form Type) Kymera Therapeutics, Inc. |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 3)1 Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 501575104 (CUSIP Number) JAMES KRAT |
|
| August 19, 2022 |
Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) S |
|
| August 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissi |
|
| August 19, 2022 |
Kymera Announces $150 Million Private Placement Equity Financing Exhibit 99.1 Kymera Announces $150 Million Private Placement Equity Financing Watertown, Mass. (August 19, 2022) ? Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain existing and new accredited investors t |
|
| August 19, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of August 18, 2022, between Kymera Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purc |
|
| August 19, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August 18, 2022, by and between Kymera Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the several purchasers identified on the signature page hereto (each, including its successors and assigns, a ?Purchaser?). RECITALS WHEREAS, the Company and the Purchaser are e |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| August 9, 2022 |
Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs, initial data to be shared by year end June 30, 2022 cash balance of $482.5 milli |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 501575104 (CUSIP Number) JAMES KRAT |
|
| May 3, 2022 |
Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs Pre-clinical data pre |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission F |
|
| April 29, 2022 |
DEF 14A 1 d234401ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ |
|
| April 29, 2022 |
DEFA14A 1 d142475ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Prox |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| February 24, 2022 |
Exhibit 10.15 SECOND AMENDMENT TO MASTER COLLABORATION AGREEMENT This Second Amendment to Master Collaboration Agreement (this ?Second Amendment?) is made and entered into as of October 21, 2021 (the ?Second Amendment Effective Date?), by and between and Vertex Pharmaceuticals Incorporated (?Vertex?) and Kymera Therapeutics, Inc. (?Company?), and amends that certain Master Collaboration Agreement |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts ACTIVE/107610297.1 |
|
| February 24, 2022 |
Lease between the Registrant and ARE-MA REGION NO. 75, LLC dated as of December 20, 2021. Exhibit 10.16 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 20th day of December, 2021, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and Kymera therapeutics, Inc., a Delaware corporation (?Tenant?). Building: The to-be-constructed building in the Project to be located at The Arsenal on the Charles, Watertown, Massachusetts 02472 (al |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEU |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Kymera Therapeutics, Inc. |
|
| February 24, 2022 |
Amended and Restated Non-Employee Director Compensation Policy dated January 17, 2022. Exhibit 10.3 KYMERA THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Kymera Therapeutics, Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the |
|
| February 24, 2022 |
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines and favorable safety profile. |
|
| February 14, 2022 |
KYMR / Kymera Therapeutics Inc / Redmile Group, LLC - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Kymera Therapeutics, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.0001 par value per share, of Kymera Therapeutics, |
|
| February 11, 2022 |
KYMR / Kymera Therapeutics Inc / Atlas Venture Fund X, L.P. - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kymera Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 11, 2022 |
Atlas Venture Fund X, L.P. SC 13G/A Exhibit A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Kymera Therapeutics, Inc. and further agree that this agreement be included a |
|
| February 10, 2022 |
KYMR / Kymera Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Kymera Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 501575104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kymera Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Kymera Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 501575104 (CUSIP Number) JAMES KRAT |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2022 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2021 |
Exhibit 99.1 Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust ex vivo inhibition of multiple disease-relevant cytokines |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2021 |
Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Appl |
|
| October 27, 2021 |
Exhibit 99.1 Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple proinflammatory cytokines observed, suggesting potent |
|
| October 27, 2021 |
Exhibit 99.2 Safety, PK and PD from Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers Jared Gollob, M.D. - Chief Medical Officer th 4 Annual TPD Summit, Keynote Plenary Session October 27, 2021 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federa |
|
| October 27, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| October 1, 2021 |
As filed with the Securities and Exchange Commission on October 1, 2021 Table of Contents As filed with the Securities and Exchange Commission on October 1, 2021 Registration No. |
|
| October 1, 2021 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named Exhibit 4.4 KYMERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.0 Designation and Terms of Securities Section 2.02 Form of Securities and Trustee?s Certificate |
|
| October 1, 2021 |
Sales Agreement, dated as of October 1, 2021 between the Registrant and Cowen and Company, LLC Exhibit 1.2 KYMERA THERAPEUTICS, INC. $250,000,000 COMMON STOCK SALES AGREEMENT October 1, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Kymera Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during t |
|
| October 1, 2021 |
Form of Senior Indenture between Registrant and one or more trustees to be named Exhibit 4.3 KYMERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities TABLE OF CONTENTS1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES Section 2.01 Designation and Terms of Securities Section 2.02 Form of Securities and Trustee?s Certificate Sect |
|
| September 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| August 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2021 |
Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiated dosing of healthy volunteers in the Multiple Ascending Dose portion of Phase 1 trial of KT-474 Expect Inve |
|
| July 2, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-257476 PROSPECTUS 4,755,000 Shares Common Stock We are offering 4,755,00 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?KYMR.? The last reported sale price of our common stock on The Nasdaq Global Market on June 30, 2021 was $48.50 per share. We are an ?emerging growth comp |
|
| June 30, 2021 |
As filed with the Securities and Exchange Commission on June 30, 2021 As filed with the Securities and Exchange Commission on June 30, 2021 Registration No. |
|
| June 28, 2021 |
Table of Contents As filed with the Securities and Exchange Commission on June 28, 2021. |
|
| June 28, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [?] Shares KYMERA THERAPEUTICS, INC. COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT June [?], 2021 Morgan Stanley & Co. LLC J.P. Morgan Securities LLC Cowen and Company, LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, NY 1002 |
|
| June 28, 2021 |
VIA EDGAR June 28, 2021 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| June 28, 2021 |
WITH TARGETED PROTEIN DEGRADATION June 28, 2021 INVENTING NEW MEDICINES KT-474 Phase 1 Clinical Trial Update Exhibit 99. |
|
| June 28, 2021 |
Exhibit 99.1 Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose After single dose administration, degradation was maintained for a |
|
| June 28, 2021 |
[Signature Page to Underwriters’ Acceleration Request] CORRESP 1 filename1.htm VIA EDGAR June 28, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Irene Paik Re: Kymera Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-257476) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 und |
|
| June 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission F |
|
| May 6, 2021 |
Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021 Oncology degrader programs KT-413 and KT-333 expected to enter clinical development in 2H 2021 Watertown, Mass. (May 6, 2021) ? Kymera Therapeutics, |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| March 17, 2021 |
Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 As confidentially submitted to the Securities and Exchange Commission on March 17, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSI |
|
| March 17, 2021 |
CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. SECTION 200.83 Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2021 |
EX-99.1 2 d142127dex991.htm EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides a Business Update Initiated Phase 1 first-in-human dosing of KT-474, a first-in-class oral IRAK4 degrader to treat immune-inflammatory diseases Declared KT-333 as STAT3 development candidate for liquid and solid tumor indications and commenced IND-enabling |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commissio |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39460 KYMERA THERAPEU |
|
| March 11, 2021 |
EX-4.3 2 kymr-ex43735.htm EX-4.3 Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The common stock, par value $0.0001 per share (“Common Stock”), of Kymera Therapeutics, Inc. (“Kymera,” “we,” or “our”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The |
|
| March 11, 2021 |
List of Subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Kymera Securities Corporation Massachusetts ACTIVE/107610297.1 |
|
| March 2, 2021 |
EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics and ph |
|
| March 2, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Kymera Therapeutics, |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Kymera Therapeutics, INC. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kymera Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 501575104 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| January 12, 2021 |
EX-99.1 Exhibit 99.1 Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its Evolution into a Fully Integrated Degrader Medicines Company Company plans Phase 1 trial initiations across three novel degrader programs by end of 2021 Initiation of the single ascending dose portion of Phase 1 trial of KT-474 in healthy volunteers anticipated in 1Q 2021 Strong financial position to su |
|
| January 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Com |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commiss |
|
| November 5, 2020 |
Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi Reported positive interim results from non-interventional study of KT-474 (IRAK4 degrader) in HS patients |
